Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
TOP Financial Group Limited has restructured its Board of Directors, increasing the board size from five to seven members and appointing Jennifer Hoi Ling Tam as Co-Chief Executive Officer and Executive Director. The company also appointed Dean Huge as an Independent Director and Yuli Yan as an Executive Director as part of a strategic corporate refresh and relocation of its global headquarters to Houston, Texas.
Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.
Liberty Global M&A Deal with DigitalBridge, TD Greystone Infrastructure and L&G
Liberty Global received EU Commission clearance for the previously announced sale of VodafoneZiggo's passive tower assets for €669 million. The transaction is part of a broader strategy to dispose of €1.2-1.4 billion in non-core assets to support the planned spin-off and listing of Ziggo Group in Amsterdam in 2027.
Counterparty
DigitalBridge, TD Greystone Infrastructure and L&G
The Progressive Corporation reported financial results for the month and quarter ended September 30, 2026, including net income of $2.54 billion for the third quarter. Net premiums written grew 4% year-over-year to $22.3 billion for the quarter, while the company's combined ratio improved to 88.7.
Cartesian Growth Corp II Debt Financing Update with CGC II Sponsor LLC
Cartesian Growth Corporation II issued an unsecured promissory note in the principal amount of $150,000 to its sponsor, CGC II Sponsor LLC. The non-interest bearing note is payable upon the company's initial business combination or winding up, with the sponsor holding an option to convert the principal into working capital warrants at $1.00 per warrant.
Counterparty
CGC II Sponsor LLC
Term
through initial business combination or winding up
Alector, Inc. approved a stock option repricing for current employees, including the CEO and Chief Accounting Officer, for options with exercise prices above $1.87. The new exercise price is set at $1.87, the current market closing price, subject to a one-year retention period to motivate and retain staff. Approximately 4.05 million shares are affected by this repricing, which previously had exercise prices as high as $33.11.
Nordicus Partners Debt Financing Update with AC Nordic ApS
Nordicus Partners Corporation issued a $75,000 promissory note to AC Nordic ApS, an entity controlled by board member Torben Jensen. The note bears interest at 6.0% per annum and is payable on demand, with proceeds intended for working capital and general corporate purposes.
Skyx Platforms Signs $12.5M M&A Deal with Deako, Inc.
SKYX Platforms Corp. completed its acquisition of Deako, Inc., which became a wholly-owned subsidiary. The consideration consisted of 25,000,000 shares of common stock, $4 million in cash, and an $8.5 million senior secured promissory note. Deako's former shareholders now own approximately 15.6% of the combined company.
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.37M of Stock
Japan Post Holdings Co. Ltd. sold 11,960 shares of Aflac Inc at $114.72 a share, worth $1.37M in total on Oct 9, 2026. Shares held after the trade: 50,357,180 (-0.0%).
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.41M of Stock
Japan Post Holdings Co. Ltd. sold 12,200 shares of Aflac Inc at $115.83 to $116.24 a share (average $115.85) in 2 transactions, worth $1.41M in total on Oct 12, 2026. Shares held after the trade: 50,344,940 (-0.0%).
Sono-Tek Corporation reported a 6% increase in net sales to $10.89 million for the six months ended August 31, 2026, compared to the prior year. Net income grew to $1.11 million, driven by improved gross margins and higher interest income, despite an increase in operating expenses and a net unrealized loss on marketable securities.
Aptevo Therapeutics announced it will present data on its multispecific platform and CD40-directed portfolio at the SITC 2026 Annual Meeting. The presentation will focus on the platform's ability to coordinate innate and adaptive immune activity within the tumor microenvironment to overcome immunosuppression in solid tumors.
Integer Holdings M&A Deal with Kohlberg Kravis Roberts & Co. L.P.
Integer Holdings Corporation provided a status update on its pending acquisition by affiliates of KKR, noting that a special meeting of stockholders to approve the merger is scheduled for October 21, 2026. The company also disclosed that it has received several stockholder complaints and demand letters alleging disclosure deficiencies in its proxy statement and has issued supplemental disclosures to address these claims.
Evolution Metals & Technologies Corp. reaffirmed its fiscal 2027 revenue guidance of $400 million to $460 million and provided an update on its magnet grade portfolio. The company also announced plans to begin acquiring equipment for samarium cobalt (SmCo) magnet production by mid-2027 to address U.S. military requirements.
Pulse Biosciences Partnership with Clayman Thyroid Center at the Hospital for Endocrine Surgery
Pulse Biosciences has entered into a commercial and clinical partnership with the Clayman Thyroid Center to utilize the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules. The collaboration involves the commercial use of the system at the Tampa-based center and a joint effort to collect real-world clinical outcomes and conduct formal studies on nsPFA energy utility.
Counterparty
Clayman Thyroid Center at the Hospital for Endocrine Surgery
Eagle Point Credit Company provided preliminary unaudited estimates for the period ended September 30, 2026, including a net asset value (NAV) per common share between $4.12 and $4.22. The company also estimated net investment income and realized losses between $0.27 and $0.31 per weighted average common share for the third quarter.
Data443 Risk Mitigation, Inc. announced the general availability of Vaikora, its AI runtime enforcement and control platform designed to govern AI agent actions and data flows in real-time. The platform provides inline controls to allow, block, or constrain AI tool calls and agent-to-agent communications, addressing a security gap as enterprises move autonomous AI agents into production.
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
CytoDyn reported a net loss of $19.9 million for the quarter ended August 31, 2026, significantly higher than the $5.5 million loss in the prior year due to a $12.3 million loss on note extinguishment. The company continues to express substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $950.4 million.
Eagle Point Income Company provided preliminary unaudited estimates for the quarter ended September 30, 2026. The company estimated its net asset value (NAV) per common share to be between $12.34 and $12.44, and its net investment income (NII) and realized losses to be between $0.65 and $0.69 per weighted average common share.
Coya Therapeutics announced plans to initiate an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS to collect long-term safety and efficacy data. Due to resource prioritization for the ALS program, the company has delayed the planned initiation of its Phase 2 trial for COYA 302 in frontotemporal dementia from late 2026 to 2027.
Datacentrex has begun the installation and energization of over 500 additional ElphaPex DG2 Scrypt ASIC miners, which were previously acquired and prepaid. Upon full deployment, the company expects its online Scrypt hashrate to increase by approximately 21% to 52.2 TH/s and its total power capacity to reach 14 MW. This expansion brings the company's total fleet to more than 3,500 miners across four U.S. colocation facilities.
EuroDry Insider Aristeidis P. Pittas Buys $35.8K of Stock
Aristeidis P. Pittas bought 700 shares of EuroDry Ltd. at $51.18 a share, worth $35.8K in total on Oct 13, 2026. Shares held after the trade: 76,788 (+0.5%).
Valion Bio highlighted the capabilities of its wholly owned CDMO subsidiary, Velocity Bioworks, to support biotechnology companies seeking domestic U.S.-based manufacturing. The update follows the implementation of Section 232 pharmaceutical tariffs, positioning Velocity's San Antonio facility as a strategic option for early-phase clinical drug substance manufacturing.
Flex Ltd. completed its acquisition of EPC Power Corp., a provider of power conversion solutions for data centers and grid applications, to strengthen its Cloud and Power Infrastructure portfolio. To fund the transaction, Flex entered into a $1.1 billion senior bridge credit facility and borrowed the full amount on October 14, 2026. The acquisition is part of Flex's strategy to address AI infrastructure power demands ahead of its planned spin-off of the segment into a new company, Axiom Solutions International, Inc.
Value
$1.1B
Counterparty
EPC Power Corp.
“EPC Power adds differentiated power conversion and grid-forming technology to our capabilities across power, cooling and compute. Together, we can help customers address the growing power demands of AI infrastructure with more efficient, resilient and integrated solutions.”
MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, a 26% year-over-year increase. The company also raised its full-year 2026 total revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million, driven by accelerated instrument purchasing and milestone payments.
Jingbo Technology, Inc. reported a net loss of $512,734 for the three months ended August 31, 2026, compared to a loss of $786,328 in the prior year period. The company remains in a significant deficit position with a total stockholders' deficit of $33,017,858 and is classified as a smaller reporting company.
Sabre $1B Debt Financing with Wilmington Trust, National Association
Sabre Corporation's subsidiary, Sabre Financial Borrower, LLC, completed a cash tender offer and subsequent redemption for all $1.0 billion of its outstanding 11.125% Senior Secured Notes due 2029. Approximately $931.6 million in notes were purchased via the tender offer, with the remaining $68.4 million redeemed at a price of 109.250% of the principal amount.
WhiteHorse Finance, Inc. declared a special distribution of $0.17 per share, payable on December 10, 2026, to stockholders of record as of October 30, 2026. The company also announced it will release its third quarter 2026 financial results on November 9, 2026.
Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.